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Abstract
Introduction: One of  the most serious threats for people infected with human immunodeficiency 
virus (HIV) is the risk of influenza co-infection and complications thereof. Not only is this population 
fundamentally more susceptible to flu but also prolonged replication and excretion of the virus, longer 
illness period, higher complication rate, flu-associated mortality, and risk of cardiovascular disease 
have all been noted.
Material and methods: The  aim of  our study was to assess vaccine efficacy against influenza in 
HIV-infected patients in various stages of  the  disease in comparison to a  control group and es-
timate the  influence of  the vaccine on respiratory system infection rates. We prospectively studied 
78 patients. Our study group included 47 patients with HIV and 31 healthy volunteers. The partici-
pants were immunised with TIV (trivalent influenza vaccine). Humoral response as an anti-AH1N1  
(A/Brisbane/59/07), -AH3N2 (A/Brisbane/10/07), and -B strain (B/Florida/4/06) haemagglutinin  
antibody titre was measured. The assay was performed twice: before administration of the vaccine and 
a month after.
Results: The HIV-infected group exhibited a weaker immune response than the control group; how-
ever, the immunisation did provide partial protection against influenza. Vaccine efficacy was similar, 
regardless of CD4 count. Trivalent influenza vaccine successfully prevented influenza-associated bac-
terial pneumonia.
Conclusions: The study demonstrates that routine vaccination against influenza in HIV-infected pa-
tients, regardless of immune system deficiency, is substantiated.
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Introduction
Human immunodeficiency virus (HIV) infection and 
acquired immunodeficiency syndrome (AIDS) remains 
a paramount public health issue across the population, in its 
course leading to a progressive immune deterioration, op-
portunistic infections, and malignancies. Since the introduc-
tion of highly active antiretroviral drugs, patients’ survival 
rates have markedly increased. Nevertheless, one of the se-
rious threats to the  population of  HIV-infected patients 
remains the  risk of  influenza infection and complications 
thereof, consisting notably of bacterial pneumonia [1]. Not 
only are HIV-infected people more susceptible to influen-
za, but also prolonged replication and excretion of the virus, 
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Vaccination
Participants were vaccinated with an inactivated vaccine 
(TIV, trivalent influenza vaccine), consistent with WHO rec-
ommendations for the 2008/2009 flu season (the study was 
conducted in 2008/2009). Fluarix, a GlaxoSmithKline prod-
uct, was used. Subsequently, humoral response as an  anti- 
AH1N1 (A/Brisbane/59/07), -AH3N2 (A/Brisbane/10/07), 
and -B strain (B/Florida/4/06) haemagglutinin antibody titre 
was measured. The measurement was taken twice: before ad-
ministration of the vaccine and a month after.
Blood tests 
Blood samples were collected in the morning (from 7.00 
a.m. to 8.00 a.m.), centrifuged (3500 g/15 min), and stored at 
–80°C until assayed. Analysis of CD4+ and CD8+ lymphocyte 
subpopulations in the blood was performed with the FACS-
Calibur flow cytometry platform (BD Biosciences, New Jer-
sey, US). Quantitative measurement of HIV RNA in patients’ 
serum was performed in vitro with the COBAS TaqMan 48 
analyser (Hoffmann-La Roche Ltd., Basel, Switzerland) as 
a nucleic acid amplification test. This assay, through real-time 
PCR technology, makes it possible to quantify HIV-1 RNA 
with a linear range of 47-10 000 000 copies/ml.  
TIV efficacy was expressed as a  defined immune re-
sponse: anti-haemagglutinin titre against administered 
vaccine antigens. Antibody concentration was obtained 
through a haemagglutination inhibition assay (according to 
WHO guidelines), using a 0.75% turkey RBC solution and 
the  recommended viral strains, manufactured in fertilised 
chicken eggs or cell cultures. Based on the obtained data, pa-
rameters of vaccine efficacy were established: protection rate 
(PR, the percentage of people who produced an antibody ti-
tre of at least 40), geometric mean titre (GMT), response rate 
(RR, the percentage of people to exhibit an at least two-fold 
increase in antibody titre), and mean fold increase (MFI, 
a geometric mean of  the  fold change before and after vac-
cination).
The study was conducted in accordance with the Dec-
laration of  Helsinki (1975) and was approved by the  local 
Ethics Committee.
Statistical methods
Analysis of  the  data was conducted using parametric 
tests. Student’s t-test was employed to compare the  anti-
body titres in the analysed groups, and ANOVA to compare 
the HIV-infected subgroups with the control group and each 
other before and after the vaccination and to compare the re-
sponse to each influenza antigen. Statistical analysis was 
performed using Statistica 10 software (StatSoft® Inc., USA). 
Statistical hypothesis testing yielded values of  p < 0.05. 
The study was conducted in accordance with the Declara-
tion of  Helsinki (1975) and approved by the  Jagiellonian 
University Ethics Committee. All study participants signed 
an informed consent form.
longer illness period, higher complication rate, flu-associated 
mortality, and risk of  cardiovascular disease have all been 
noted in that population [2-4]. Lin et al. demonstrated that 
in a  group of  patients with AIDS, the  flu-associated mor-
tality rate is far higher (94-146/100 000) than in the  gen-
eral population (0.9-1.0/100 000 for ages 25-45 years and 
64-70/100 000 for ages 65 years and over). It has also been 
shown that the  risk of  hospitalisation caused by a  respira-
tory/cardiovascular condition in HIV-infected women is 
markedly higher during the  flu season  [5, 6]. Additional 
factors in a portion of the population, such as smoking, use 
of  inhaled narcotics, and chronic respiratory diseases in-
crease the risk of infection even more [7].
Vaccination is one of the classic methods of preventing 
infection. Vaccinating people with impaired immunity, re-
gardless of the cause of impairment, presents two basic prob-
lems: the first is the possibility of adverse effects following 
vaccination. In HIV-infected patients, particularly with CD4 
count below 200/µl, attenuated (“live”) vaccines should not 
be used because of  the  immune deficiency. Live vaccines 
against cholera, typhoid fever, flu, tuberculosis, polio (OPV), 
and smallpox are contraindicated regardless of CD4 count. 
Killed vaccines, however, are as safe for immunodeficient 
patients as they are for the immunocompetent. The second 
problem is an insufficient or even non-existent response to 
vaccination, which, again, stems from the  impairment to 
the  immune system. In HIV-infected patients it is recom-
mended to defer use of  inactivated vaccines until the CD4 
count exceeds 200/µl [1].
The aim of  our study was to assess vaccine efficacy 
against influenza in HIV-infected patients in various stages 
of the disease in comparison to a control group and estimate 
the influence of the vaccine on respiratory system infection 
rates.
Material and methods
Patients
We prospectively studied 78 patients. Our study group 
consisted of  47 patients: 11 females (23.4%) and 36 males 
(76.6%), aged between 19 and 52 years (age average: 36.3 
years) with HIV, treated at the Infectious and Tropical Dis-
eases Department, University Hospital in Krakow, and 31 
healthy volunteers: 10 females (32.3%) and 21 males (67.8%) 
aged 22 to 50 years (average: 26.5 years). The  diagnosis 
of HIV infection was based on the detection of HIV-specific 
antibodies with an ELISA test (Hoffmann-La Roche Ltd., Ba-
sel, Switzerland), confirmed by a Western-blot (INNO-LIA, 
Fujirebio Inc., Pennsylvania, US). The  HIV-infected group 
was divided into two subgroups: one with CD4 count un-
der 350/µl and the second over 350/µl. The exclusion criteria 
were: contraindications to the  influenza vaccine, autoim-
mune disorders, diseases associated with immunosuppres-
sion, diabetes, and, in the control group, HIV infection.
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Results
Vaccine efficacy in the studied groups
Both groups were demonstrated to show significantly 
higher anti-haemagglutinin antibody titre values one month 
after vaccination in comparison to the titre before immunisa-
tion. TIV was efficacious for the whole analysed population. 
It was shown that anti-haemagglutinin specific antibody 
titre values were significantly higher one month after vacci-
nation in both groups. TIV in the HIV-infected patient group 
with CD4 count below 350/µl was efficacious as well.
Disparity in protective antibody 
titres between the HIV-group and 
the control group before and after 
immunisation 
Differences in antibody titre between the analysed groups 
were compared before administering the  vaccine. Although 
titres of  all the  tested antibodies were noticeably higher in 
the control group in comparison to the HIV-infected group, 
the differences were not statistically significant (Fig. 1). A sim-
ilar comparison was made of the titre in the analysed groups 
one month after immunisation. The  mean antibody titre 
against AH3N2 after immunisation in the HIV-infected group 
was significantly lower than in the  control group. The  rest 
of the range did not show statistical significance (Fig. 2).
Response to vaccine antigens in 
the HIV-infected group 
In the HIV-infected patient group average values of anti- 
H1, -H3, and -B anti-haemagglutinin titre values were var-
ied. The  strongest response observed was to the  AH1N1 
strain and the  weakest for B/Florida/4/06. A  statistically 
significant difference, however, was only observed between 
antigen AH1N1 and B antibody titre (p = 0.008) (Fig. 3).
Table 1. Mean titres of anti-haemagglutinin antibodies for the AH1N1, AH3N2, and B strains in HIV-infected patients and 
the control group before immunisation and one month after
Antibody type
Control group (n = 31) HIV-infected patients (n = 47)
Antibody titre (mean ± SD) p Antibody titre (mean ± SD) p
Anti-H1 before immunisation 18.1 ± 56.5
0.001
8.1 ± 11.4
0.001
Anti-H1 after one month 315.5 ± 450.3 185.1 ± 361.1
Anti-H3 before immunisation 35.6 ± 115.8
0.001
10.7 ± 16.6
0.006
Anti-H3 after one month 320.8 ± 464.6 121.70 ± 273.9
Anti-B before immunisation 10.9 ± 14.9
0.004
9.6 ± 23.1
< 0.001
Anti-B after one month 75.9 ± 119.3 39.3 ± 68.5
Table 2. Mean titres of anti-haemagglutinin antibodies for the AH1N1, AH3N2, and B strains in HIV-infected patients before 
immunisation and one month later in relation to CD4 count
Antibody type
HIV-infected patients, CD4 < 350/µl 
(n = 29)
HIV-infected patients, CD4 > 350/µl 
(n = 18)
Antibody titre (mean ± SD) p Antibody titre (mean ± SD) p
Anti-H1 before immunisation 6.6 ± 4.0
0.03
10.6 ± 17.7
0.03
Anti-H1 after one month 149.3 ± 328.1 242.8 ± 412.1
Anti-H3 before immunisation 11.7 ± 20.0
0.03
9.2 ± 9.1
0.01
Anti-H3 after one month 117.2 ± 261.8 128.9 ± 299.9
Anti-B before immunisation 10.7 ± 28.7
0.02
7.8 ± 8.8
0.002
Anti-B after one month 43.6 ± 83.6 32.2 ± 32.9
Figure 1. Antibody titre in each group before immunisation
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Calculation of the parameters 
conductive to the assessment 
of vaccine efficacy
The values of  the  first two parameters (PR and GMT) 
may be overestimated, since a  fraction of  the  patients had 
already been immunised (seropositive before vaccination). 
The last two parameters, namely RR and MFI, account for 
the change dynamic, but may in turn underestimate the re-
sults [8]. The parameters used to evaluate the influenza vac-
cination efficacy are presented in Table 3.
Incidence of sequelae bacterial 
respiratory infections
Based on patients’ medical records, no complications in 
the form of bacterial respiratory tract infections (pneumo-
niae) were found. 
Discussion
Yearly vaccination is the most effective method of pre-
venting influenza and its complications. The most commonly 
used vaccines are inactivated and consist of  three viruses: 
two different influenza type A strains and one influenza 
type B strain. Due to high mutation rate of  the  virus, 
the  WHO issues annual recommendations for influenza 
vaccine formulations before every flu season. The markers 
of  post-immunisation protection are anti-haemagglutinin 
and virus-neutralising antibody titres in the serum. An in-
crease in antibody titre post-vaccination lowers the  risk 
of  disease caused by strains similar to those included in 
the  vaccine. Parameters such as PR (usually defined as 
haemagglutination titre of 1 : 32 or 1 : 40) correlate well with 
immunity at a population level [9, 10].
According to the  requirements of  the  Commission 
of the European Communities and the Committee for Pro-
prietary Medicinal Products for influenza vaccination for 
people aged 18-60 years, average antibody level MFI should 
be ≥ 2.5, PR ≥ 70%, and RR ≥ 40%. In our study the immu-
nisation induced a  significant titre of  anti-haemagglutinin 
antibodies in all the participants. In the control group, the in-
crease in antibody level averaged from 4.3 (B strain) through 
8.6 (AH1N2) to 15.3 (AH1N1). PR > 70% was achieved for 
the AH1N1 and AH3N2 strains; only for the B strain was 
Figure 2. Antibody titre in each group after immunisation Figure 3. Response to vaccine antigens in HIV-infected patients
Table 3. Parameters of influenza vaccine efficacy in studied groups
Antigen Group
GMT MFI PR [%] RR [%]
Before 
immunisation
One month 
after 
immunisation
One month 
after 
immunisation
Before 
immunisation
One month 
after 
immunisation
One month 
after 
immunisation
A/Brisbane/59/07 
(H1N1)
HIV 6.2 35.0 5.6 2.1 51.1 57.5
Control 7.3 111.9 15.3 6.5 83.9 74.2
A/Brisbane/10/07 
(H3N2)
HIV 6.9 27.3 3.9 10.6 44.7 48.9
Control 9.8 83.7 8.6 16.1 74.19 67.7
B/Florida/4/06
HIV 5.9 15.1 2.6 4.3 36.2 38.3
Control 7.5 32.7 4.4 6.5 54.8 54.8
GMT – geometric mean titre, MFI – mean fold increase, PR – protection rate, RR – response rate
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it 54.8%. Response rates fluctuated between 54.8% and 
74.1%. In a healthy population the vaccine is usually highly 
immunogenic and effective, which proved to be true in our 
study as well. The HIV-infected patients exhibited a weaker 
response to the immunisation. Antibody GMT after vacci-
nation was 2-3 times lower than in the control group; statis-
tical significance, however, was shown only in the response 
to AH3N2 antigen. Despite that, MFI exceeded the recom-
mended level of 2.5 for all the strains. PR fluctuated between 
36.1% (B strain) and 51% (AH1N1 strain) and did not reach 
the desirable level of 70%. RR exceeded 40% for the first two 
strains, and for the B strain it was 38.2%, essentially meeting 
the requirements [11-14].
Analysis of  studies comparing incidence rates of  influ-
enza among vaccinated and unvaccinated HIV-infected pa-
tients has indicated a moderate advantage of vaccinating [3, 
15-17]. Mahdi et al. conducted an  extensive, randomised, 
double-blind trial among HIV-infected citizens of  Johan-
nesburg, South Africa. It yielded a  percentage of  serocon-
version of  52.6-60.8%. The  average increase in antibody 
concentration ranged from 4.1-10.2, which was higher than 
in our study. Efficacy in preventing laboratory-confirmed 
influenza was high and reached 75.5%  [18]. Atashili et al. 
conducted a  meta-analysis of  four studies, encompassing 
646 HIV-infected patients in total, and found TIV to be 
moderately efficacious in limiting the  influenza incidence 
rate  [19]. The  only study on an  adult HIV-infected popu-
lation in Poland involved 34 patients. PR after a  month 
ranged from 18% (AH1N1 strain) through 41% (B strain) 
to 79% (AH3N2 strain). However, the value for the latter has 
been overestimated due to a high percentage (50%) of pa-
tients with a  pre-existing high protective antibody titre. It 
stemmed from prior contact with said subtype, which dom-
inated at that time in Poland. Antibody GMT increased by 
a factor of 1.5-5.5, which is comparable to our results, yield-
ing an  increase by a  factor of  2.6-5.6. Like here, no statis-
tically significant difference in humoral response between 
patients with different CD4 values nor between patients in 
different clinical stages of the disease was shown [20].
CD4 count is a  key factor in immune system function 
of HIV-infected patients. As the disease progresses, the B me- 
mory cell function declines, which is particularly evident in 
patients with high viral load. Hence, they exhibit a weaker 
humoral response to immunisation. It has been established 
that the  independent factors correlated with post-vaccina-
tion response strength are CD4 count and viral load [21, 22]. 
Low CD4 count, especially < 200/µl, reduces vaccine efficacy 
in general and similarly for the influenza vaccine [23-25]. It 
has been shown that in patients with high CD4 count the im-
munisation induced a  high specific protective antibody ti-
tre [23, 24, 26]. Patients in the AIDS phase, in turn, often did 
not achieve a  protective antibody titre  [23, 24]. Moreover, 
administration of a second dose of the vaccine did not im-
prove the response [23, 27]. In a randomised trial in children 
with average CD4 count above 400/µl, immunisation was 
efficacious in preventing laboratory-confirmed influenza at 
a  similar rate as in the general population [28]. Fine et al. 
showed efficacy only in patients whose CD4 count exceeded 
100/µl or whose viral load was under 30 000/ml  [3]. Fur-
thermore, patients undergoing antiretroviral therapy (ART) 
longer than three months, with a CD4 count increase of at 
least 15% and viral load decrease to under 1000 copies/ml, 
respond better to treatment. An additional benefit of ART is 
an increase in concentration of specific antibodies left over 
from prior immunisations when no booster dose has been 
given. It has been shown that immunogenicity of the influ-
enza vaccine is higher in patients successfully treated with 
ART and without progression of the disease [29]. Our study 
did not find such a relation. TIV was efficacious for patients 
with CD4 counts both over and under 350/µl. Presumably 
application of a different patient distribution (with a signifi-
cantly lower CD4 count) would show an impact of a nomi-
nal CD4 cell level on vaccine efficacy in said groups.
Influenza, in contrast to many diseases entirely pre-
ventable with immunisation, is very common with a  high 
incidence rate worldwide. That poses a challenge for stud-
ies on vaccine immunogenicity because a  sizeable portion 
of  the  studied population may already have a  protective 
antibody titre from prior contact with a  given virus upon 
entrance into the  study. In our study, the  geometric mean 
of  antibody titres was low and in HIV-infected patients 
was in the  range of 5.97 to 6.24, and in the  control group 
7.31 to 9.77. No statistically significant difference between 
the groups was shown. This proves that most patients had 
not had prior contact with viral antigens corresponding to 
vaccine antigens.
Inactivated influenza vaccines available in Poland con-
tain three flu strain antigens. One element of the study was 
an  assessment of  the  response to individual antigens in 
HIV-infected patients, where a  weaker response was ob-
served to the B strain. This tendency has not been backed by 
any of the quoted publications by other authors and possibly 
stems from a weaker immunogenicity of the antigen used in 
said flu season.
In a typical flu season in Poland (autumn to early spring 
months) we observe raised mortality and hospitalisation 
rates during the circulation of the virus. Based on the cor-
relation between influenza activity and seasonality of pneu-
mococcal pneumonia, one could infer that in some patients 
admitted for invasive pneumococcal pneumonia we might 
expect a comorbid influenza infection [30]. The unnecessary 
deaths and admissions in flu season, which are, at least part-
ly, caused by influenza infection, fit into a  broad category 
of  respiratory and circulatory hospitalisations  [31, 32]. In 
our study we analysed medical records of HIV-infected pa-
tients, finding no instances of bacterial respiratory infections 
throughout nine months post-vaccination. We can therefore 
speculate that TIV in HIV-infected patients successfully 
prevents complications in the  form of  pneumonia. A  me-
ta-analysis of 15 cohort studies and clinically controlled tri-
als evaluating the factual effectiveness of TIV in preventing 
flu/pneumonia-associated hospitalisations in patients above 
65 years old showed that TIV use helped avert 6-26% of doc-
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tor visits and reduced the relative risk of death due to flu or 
pneumonia [33].
In conclusion, immune response to influenza vaccina-
tion was weaker in HIV-infected patients than in the healthy 
population; nevertheless, the  immunisation did provide 
partial protection against the flu. Vaccine efficacy was com-
parable regardless of CD4 count. Immunisation successful-
ly prevented flu-associated bacterial pneumonia. The study 
demonstrates that routine vaccination against influenza in 
HIV-infected patients, regardless of  immune system defi-
ciency, is substantiated.
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